Products with
Anticancer bioactivity
Cat.No.
|
Product Name
|
BCN2954 |
Desoxyrhaponticin
|
Desoxyrhaponticin is an agent that is potentially effective in controlling postprandial hyperglycemia in diabetes. Desoxyrhaponticin could be considered as a promising fatty acid synthase(FAS) inhibitor, it could inhibit intracellular FAS activity and downregulate FAS expression in human breast cancer MCF-7 cells. |
BCN2955 |
Tubeimoside II
|
Tubeimoside I, tubeimoside II, and tubeimoside III show anti-inflammatory, antitumor, and antitumor-promo ting effects. |
BCN2956 |
Tubeimoside III
|
Tubeimoside III has anti-inflammatory, anti-tumor, and anti-tumorigenic activities, stronger than those of tubeimoside II. It has acute toxicity, stronger than that of tubeimoside II. |
BCN2961 |
Ingenol 3-Angelate
|
1. Ingenol-3-angelate suppresses HIV infection of primary CD4+ T cells through down-modulation of cell surface expression of HIV co-receptors.
2. Ingenol 3-angelate activates a broad range of PKC isoforms and induces apoptosis in acute myeloid leukemia cells by activating the PKC isoform PKCdelta.
3. Ingenol-3-angelate shows anticancer activity, and P-gp-mediated absorptive transport, dermal penetration, and vascular damage contribute to the anticancer activity of ingenol-3-angelate in vivo.
4. Ingenol-3-angelate emerges as a unique local chemotherapeutic immunostimulatory debulking agent that could be used in conjunction with immunotherapies to promote regression of metastases. |
BCN2964 |
Cyclopamine
|
Cyclopamine is a Hedgehog (Hh) pathway antagonist with an IC50 of 46 nM in the Hh cell assay, it can increase levels of p27, and decreases both expression of IGF-II and activation of Akt in PC-3 prostate cancer cells. Cyclopamine as a novel, potent inhibitor of human breast cancer proliferation and estrogen responsiveness that could potentially be developed into a promising therapeutic agent for the treatment of breast cancer. Cyclopamine also can suppress the growth of leukemia and lymphoma cells. |